Top-News
Sonntag,
21.05.2017 16:05
von
PR Newswire
| Aufrufe: 190
Clinical Trial Published in JAMA Offers New Hope for COPD Patients
Ein Mann liest Wirtschaftsnachrichten (Symbolbild).
pixabay.com
PR Newswire
WASHINGTON, May 21, 2017
WASHINGTON, May 21, 2017 /PRNewswire/ -- People suffering from chronic obstructive pulmonary disease (COPD) – the third leading cause of death in the United States – may see their lives change thanks to a ResMed-sponsored clinical trial (NYSE: RMD) presented at the 2017 American Thoracic Society International Conference and published in the Journal of the American Medical Association (JAMA) today.
The trial, Home Oxygen Therapy - Home Mechanical Ventilation (HOT-HMV), was designed to investigate the effect of using non-invasive ventilation (NIV) at home on time to hospital readmission or death. Patients in the study had persistent hypercapnia (high levels of carbon dioxide in their blood) and had recently been hospitalized for a worsening of their COPD.
Patients in the study who received NIV at home in addition to oxygen therapy had a 51 percent decreased risk of re-hospitalization or death, and stayed out of the hospital more than three times longer, compared to those who received oxygen alone.
"This trial adds decisively to the growing body of evidence supporting the broader use of non-invasive ventilation for patients with COPD," said ResMed chief medical officer Carlos Nunez, M.D. "Just knowing NIV can help cut re-hospitalization or death risk in half is a game changer."
The Global Initiative for Obstructive Lung Disease, an international collaboration of experts on COPD, recently updated their guidelines to include a level B recommendation for home NIV for hypercapnic COPD patients after an exacerbation.
Economic Impact
The number of people with COPD globally is estimated to be 384 million1. In 2014, the Centers for Disease Control and Prevention (CDC) estimated COPD cost the United States $36 billion annually in medical costs and absenteeism, and projected medical costs alone related to COPD could rise to $49 billion by 2020.
ARIVA.DE Börsen-Geflüster
Werbung
Weiter abwärts?
| Kurzfristig positionieren in ResMed | ||
|
ME5SUH
| Ask: 2,23 | Hebel: 7,12 |
| mit moderatem Hebel |
Zum Produkt
| |
Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: ME5SUH,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Kurse
 |
 |
One reason is that nearly one in four COPD patients in the U.S. who leave the hospital after an acute exacerbation will be re-hospitalized within 30 days, driving increased costs to the healthcare system and significantly impacting the patients' quality of life.
To curb the financial impact of this re-hospitalization, the U.S. Centers for Medicare and Medicaid Services now penalizes hospitals with high readmission rates after an acute exacerbation of COPD.
About the HOT-HMV Study
More details on the study can be found on the JAMA website: http://jamanetwork.com/journals/jama/fullarticle/2627985.
About COPD
COPD is a collection of lung diseases including chronic bronchitis and emphysema. It is a progressive, fatal condition that causes irreversible damage to the lungs and airways. It can have a major impact on an individual's quality of life. It is the third leading cause of death in the U.S. and is the only major disease that is increasing in prevalence globally, across all continents.
During the course of their disease, COPD patients can experience acute exacerbations, which manifest themselves as a sudden worsening of symptoms and can lead to respiratory failure, hospitalization and death. Although the damage caused by COPD cannot be reversed, it is possible to slow the progression of the disease through treatment and lifestyle changes.
About ResMed
ResMed (NYSE: RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries. ResMed.com | Facebook | Twitter | LinkedIn
1 Global and regional estimates of COPD prevalence: Systematic review and meta–analysis, Journal of Global Heath, 2015
| For media: | For investors: |
| Alison Graves | Agnes Lee |
| 858-836-6789 | 858-836-5971 |
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/clinical-trial-published-in-jama-offers-new-hope-for-copd-patients-300461130.html
SOURCE ResMed Inc.
Werbung
Mehr Nachrichten zur ResMed Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Andere Nutzer interessierten sich auch für folgende News
09:12 - PR Newswire
